SlideShare a Scribd company logo
www.drugregulations.org 1
Presentation prepared by Drug Regulations – a not for profit
organization. Visit www.drugregulations.org for the latest in
Pharmaceuticals.
 This presentation will cover
1. Overview of Quality Risk Management
Process & Tools
2. FMEA Overview
3. Calculation of RPN
4. Case Stud
◦ Drying Process
www.drugregulations.org 2
 Risk
◦ Combination of
◦ Probability of occurrence of harm and
◦ Severity of that harm.
 Any circumstances which can cause an
adverse health effect.
◦ Research , Pre-clinical , Clinical
◦ Production
◦ Control
◦ Distribution
 Which consequence is more severe?
◦ 300 lives lost in single, fiery plane crash.
◦ 300 lives lost on roads over a weekend.
◦ 300 lives potentially lost from cancer within the next 20 years
 Which probability is probable?
What does a “30% chance of rain tomorrow” mean?
◦ 30% of the days like tomorrow will have at least a trace of rain.
◦ 30% of the area will have rain tomorrow.
◦ 30% of the time tomorrow, it will rain.
Hazard
may
cause harm
Hazard
may not
cause harm
uncertainty
Hazard
is less likely to
cause harm
Manage risks
in relation to
probability
Lack of, or inadequate knowledge
Time 
ProcessParameter
Lower Specification Limit (LSL)
Upper Specification Limit (USL)
today
Uncertainty
RISK: For a given severity of risk event, what are the chances
(probability) of exceeding the USL in the next period of time?
Tomorrow ?
Time 
ProcessParameter
Lower Specification Limit (LSL)
Upper Specification Limit (USL)
today
Uncertainty
RISK: Control options are scenarios for risk management.
Note that this scenario shows the best estimate is below the USL.
Tomorrow ?
Time 
ProcessParameter
Lower Specification Limit (LSL)
Upper Specification Limit (USL)
today
Uncertainty
Take a cut at a moment
in time:
Risk has a distribution.
Tomorrow ?
 Risk Identification
What might go wrong?
 Risk Analysis
What is the likelihood (probability) it will go
wrong
 What are the consequences (severity)?
 Risk Evaluation
What is the level of risk? Any mitigating factors?
Risk Assessment
www.drugregulations.org 10
Risk Review
RiskCommunication
Risk Assessment
Risk Evaluation
unacceptable
Risk Control
Risk Analysis
Risk Reduction
Risk Identification
Review Events
Risk Acceptance
Initiate
Quality Risk Management Process
Output / Result of the
Quality Risk Management Process
RiskManagementtools
 Risk Reduction
Mitigation or avoidance of quality risk
Elimination of risks, where appropriate
Risk Control
 Risk Acceptance
Acceptance of Residual Risk
 System Risk (facility & people)
◦ e.g. interfaces, operators risk, environment,
components such as equipment, IT, design elements
 System Risk (organisation)
◦ e.g. Quality systems, controls, measurements,
documentation, regulatory compliance
 Process Risk
◦ e.g. process operations and quality parameters
 Product Risk (safety & efficacy)
◦ e.g. quality attributes:
measured data according to specifications
The evaluation of
the risk to quality
should be based on
scientific knowledge
and ultimately link
to the protection
of the patient
The level of effort,
formality and
documentation
of the quality risk
management process
should be
commensurate with the
level of risk
ICH Q9
 Supporting statistical tools
◦ Acceptance Control Charts (see ISO 7966)
◦ Control Charts (for example)
 Control Charts with Arithmetic Average and
Warning Limits (see ISO 7873)
 Cumulative Sum Charts; “CuSum” (see ISO 7871)
 Shewhart Control Charts (see ISO 8258)
 Weighted Moving Average
◦ Pareto Charts
◦ Process Capability Analysis
◦ Histograms
◦ Design of Experiments (DOE)
◦ Use others that you are familiar with….
www.drugregulations.org 14
158/27/2016
Drug Regulations : Online Resource for Latest Information
 Systematic Method for Identification and
Prevention of
 Product & Process Problems before they occur
 Focused on Preventing Defects
 Ideally conducted in Product & Process Design
Stage
 Conducting on existing products & processes
yields substantial results.
168/27/2016
Drug Regulations : Online Resource for Latest Information
 First formal FEMA was conducted in Aerospace Industry in
1960’s
 Became key tool for improving safety of chemical
processes
 Safety FMEA today is a key tool to prevent safety accidents
& incidents
 Engineers have always used FMEA to identify potential
failures of product & processes
 Automotive Industry used FMEA for Quality Improvement
178/27/2016
Drug Regulations : Online Resource for Latest Information
 Essential to have documented Data and Information
about Product & Process
 Otherwise it becomes a guessing game based on
opinions.
 FMEA will then focus on wrong failure modes
 FMEA should be based on facts : on DATA
188/27/2016
Drug Regulations : Online Resource for Latest Information
 To look for all different ways in which a product or
process can fail
 Failures are not limited to products
 Failures can occur when the user makes a mistake
 These failures should also be included in FMEA
198/27/2016
Drug Regulations : Online Resource for Latest Information
 Ways in which a product or process can fail are called
FAILURE MODES
 Each FAILURE MODE has a potential effect
 Some effects are more likely to occur than others –
each failure mode has a probability
 Each FAILURE MODE has relative RISK associated with
it.
208/27/2016
Drug Regulations : Online Resource for Latest Information
 FMEA process is way to identify the failures, effects,
and risks within a process or product and then
eliminate or reduce them.
218/27/2016
Drug Regulations : Online Resource for Latest Information
 Process Step : Pre-mixing
 Failure Mode : Mixing time
 Effect : Not meet specifications of content uniformity
 Risk Reduction: IPC measure of content uniformity
 Comments: Effect on efficacy
228/27/2016
Drug Regulations : Online Resource for Latest Information
 Process Step : Pre-mixing granulation
 Failure Mode : speed of adding water
 Effect : Not meet specifications of dissolution and
degradation
 Risk Reduction: Use of dosing pump
 Comments: Appropriate granulation
238/27/2016
Drug Regulations : Online Resource for Latest Information
 Process Step : Pre-mixing granulation
 Failure Mode : Manner of adding water
 Effect : Not meet specifications of dissolution and
degradation
 Risk Reduction: Install a spray nozzle
 Comments: Appropriate granulation
248/27/2016
Drug Regulations : Online Resource for Latest Information
 Process Step : Granulation
 Failure Mode : Kneading Time
 Effect : Not meet dissolution specification
 Risk Reduction: Reduce Personal fluctuations
 Comments: Operator knowledge , power
consumption, difficult to automate
258/27/2016
Drug Regulations : Online Resource for Latest Information
 Process Step : Granulation
 Failure Mode : Power consumption
 Effect : Not meet dissolution specification
 Risk Reduction: Try to get optimum kneading time
 Comments: Depends on material properties
268/27/2016
Drug Regulations : Online Resource for Latest Information
 Process Step : Granulation
 Failure Mode : Quality of excipients
 Effect : All parameters may need re-evaluation
 Risk Reduction: Internal specifications for physical
parameters
 Comments: Supplier qualification
278/27/2016
Drug Regulations : Online Resource for Latest Information
 Process Step : Granulation drying
 Failure Mode : Water Content
 Effect : Not meet degradation specification
 Risk Reduction: On line NIR , IPC measurements,
 Comments: Indirect , Time consuming
288/27/2016
Drug Regulations : Online Resource for Latest Information
 The relative risk of a failure and its effects is
determined by three factors
 Severity: The consequences of the failure should it
occur
 Occurrence: The probability or the frequency of the
failure occurring
 Detection : The probability of the failure being
detected before the impact of the effect is realized.
298/27/2016
Drug Regulations : Online Resource for Latest Information
 Each Potential Failure Mode is rated in each of the
three factors on a scale ranging from 1 to 10 , low to
high.
 Risk Priority Number( RPN) is determined by
multiplying the ranking of the three factors ( severity
X occurrence X detection )
 The RPN is determined for each potential failure and
each effect.
308/27/2016
Drug Regulations : Online Resource for Latest Information
 The RPN is used to rank the need for corrective action
to eliminate or reduce the potential failure modes.
 Failure modes with highest RPN should be attended
first
 Special attention should be given when the severity
ranking is high : 9 or 10
 RPN will range from 1 to 1000 for each failure mode.
318/27/2016
Drug Regulations : Online Resource for Latest Information
 Once corrective action is taken , a new RPN is
determined by re-evaluating the severity , occurrence
and detection.
 The new RPN is called “ Resulting RPN”
 Improvements and corrective actions must continue
until the “ Resulting RPN is at an acceptable level for
all potential failure modes.
328/27/2016
Drug Regulations : Online Resource for Latest Information
33
Start
End
Risk
identification
Risk
analysis
Etc.
Process-
step
Decision
Feedback
procedure
Start
End
Start
End
Sub-
process
Sub-Sub-
process
Potential Areas of Use(s)
 Prioritize risks
 Monitor the effectiveness of risk control activities
 Equipment and facilities
 Analyse a manufacturing process to identify high-risk
steps or critical parameters
RNP: Risk Priority Number
348/27/2016
Drug Regulations : Online Resource for Latest Information
1. Review the Process or Product
2. Brainstorm potential failure modes
3. List Potential effects of each failure mode
4. Assign a Severity Ranking for each failure mode
5. Assign Occurrence Ranking for each failure mode
6. Assign detection ranking for each failure mode or effect
7. Calculate the RPN for each effect
8. Prioritize the Failure Modes for Action
9. Take action to eliminate or reduce high risk failure modes
10. Calculate the RPN again as the failure modes are reduced or
eliminated.
358/27/2016
Drug Regulations : Online Resource for Latest Information
9/17/2015. 368/27/2016
10 Dangerously High Failure could lead to death or permanent injury to the customer. Financial:
>$1,000,000
9 Extremely high Failure could lead to injury to the customer. Failure would create non-
compliance with registered specifications. Failure likely to lead to recall.
Financial: $1,000,000
8 Very High Failure could lead to adverse reaction for customer. Failure would create
noncompliance with GMP regulations or product registrations. Failure
possible to lead to recall. Financial: $500,000
7 High Failure leads to customer percept ion of safety issue. Failure renders
individual unit(s) unusable. Failure causes a high degree of customer
dissatisfaction. Recall for business reasons possible but Authority required
recall unlikely. Financial: $100,000
6 Moderate Failure causes a high degree of customer dissatisfaction and numerous
complaints. Failure unlikely to lead to recall. Financial: $50,000
5 Low Failure likely to cause isolated customer complaints. Financial: $10,000
4 Very Low Failure relates to non-dosage form issues (like minor packaging problems)
and can be easily overcome by the customer. Financial: $5,000
3 Minor Failure could be noticed by the customer but is unlikely to be perceived as
significant enough to warrant a complaint.
2 Very Minor Failure not readily apparent to the customer. Financial: <$1,000
1 None Failure would not be noticeable to the customer. Financial: none
10 Very High: Failure
is almost
inevitable
More than one occurrence per day or a probability of more than three
occurrences in 10 units (Cpk < 0.33 or <1σ).
9 One occurrence every three to four days or a probability of three occurrences
in 10 units (Cpk ~ 0.33 or ~1 σ).
8 High: Repeated
failures
One occurrence per week or a probability of 5 occurrences in 100 units (Cpk ~
0.67 or ~2 σ).
7 One occurrence every month or one occurrence in 100 units (Cpk ~ 0.83 ~2.5
σ).
6 Moderate:
Occasional
Failures
One occurrence every three months or three occurrences in 1,000 units (Cpk ~
1.00 or ~ 3 σ).
5 One occurrence every six months to one year or one occurrence in 10,000
units (Cpk ~ 1.17 or ~ 3.5 σ).
4 One occurrence per year or six occurrences in 100,000 units (Cpk ~ 1.33 or ~ 4
σ).
3 Low: Relatively
few Failures
One occurrence every one to three years or six occurrences in 10,000,000
units (Cpk ~ 1.67 or ~5 σ).
2 One occurrence every three to five years or 2 occurrences in 1,000,000,000
units (Cpk ~ 2.00 OR ~6 σ).
1 Remote: Failure is
unlikely
One occurrence in greater than five years or less than two occurrences in
1,000,000,000 units (Cpk > 2.00 OR >6 σ).
For batch failures use the time scale for unit failures use the unit scale.
10 Absolute
Uncertainty
The product is not inspected or the defect caused by the failure is not
detectable.
9 Very Remote Product is sampled, inspected, and released based on Acceptable Quality
Level (AQL) sampling plans.
8 Remote Product is accepted based on no defects in a sample.
7 Very Low Product is 100% manually inspected in the process.
6 Low Product is 100% manually inspected using go/no-go or other mistake-proofing
gauges.
5 Moderate Some Statistical Process Control (SPC) is used in the process and product is
final inspected off-line.
4 Moderately High SPC is used and there is immediate reaction to out-of-control conditions.
3 High An effective SPC program is in place with process capabilities (Cpk) greater
than 1.33.
2 Very High All product is 100% automatically inspected.
1 Almost Certain The defect is obvious and there is 100% automatic inspection with regular
calibration and preventive maintenance of the inspection equipment.
• 10 Extreme
• Predicted to cause severe impact to quality (Product out of specifications, no
Expert Statement possible)
• 7 High
• Predicted to cause significant impact on quality (Failure to meet specifications,
no Stability data, Expert Statement possible)
• 3 Moderate
• Predicted to cause minor impact on quality (Failure to meet specifications,
Stability data available)
• 1 Low
• Predicted to have no/minor impact on quality of the product (Quality within
specifications)
9/17/2015. 408/27/2016
• 8 Regular failures
• Expected to happen regularly
• 4 Repeated failures
• Expected to happen in a low frequency
• 2 Occasional failures
• Expected to happen infrequently
• 1 Unlikely failures
• Unlikely to happen
9/17/2015. 418/27/2016
• 4 Normally not detected
• Failure very likely to be overlooked, hence not detected
(no technical solution, no manual control)
• 3 Likely not detected
• Failure may be overseen
(manual control, spot checks)
• 2 Regularly detected
• Failure will normally be detected
(manual control, routine work with statistical control)
• 1 Always detected
• Failure can and will be detected in all cases
(monitoring, technical solution available)
428/27/2016
438/27/2016
 Severity (S)
◦ Link to end product functional failure
◦ Medical Department involvement
 Probability (P)
◦ Use historical data
◦ Similar processes products
 Detection
◦ Validation studies
◦ Historical data
Drying Process
448/27/2016
Rankin
g
Severity (S) Probability (P) Detection (D)
10 Death More than once a day Impossible to detect
9 ↓ 3 – 4 times a day Remote
8 Permanent injury Once a week Very slight
7 ↓ Once a month Slight
6 Temporary injury Once in three month Low
5 ↓ Once in half – one year Medium
4
Reported/
dissatisfied
Once a year Moderately high
3 ↓ Once in 1 – 3 years High
2 Notice/ no report Once in 3 – 5 years Very High
1 ↓
Less than once in 5
years
Virtually certain
Drying Process
9/17/2015. 45
Process
Potential Failure
Mode
Potential Cause S P D RPN
1. Set up Contamination Disheveled gown of operator
Insufficient cleaning of
equipment
2. Start
drying
Contamination Damage of inlet-air filter
Degradation of
product
Damage of thermometer
3. Maintain
temperature
Long drying time Unstable supply-air volume
High Loss On Drying
(LOD)
Damage of timer
Low LOD High dew-point
Non-uniformity of
LOD
Uneven temperature
distribution
Drying Process RPN: Risk Priority Number = S*P*D
Existing controls: IPC of LOD and degradation product after drying process
Drying Process
Process
Potential Failure
Mode
Potential Cause S P D RPN
1. Set up Contamination Disheveled gown of operator 3 5 8 120
Insufficient cleaning of
equipment
7 2 8 112
2. Start
drying
Contamination Damage of inlet-air filter 7 3 6 126
Degradation of
product
Damage of thermometer 7 3 3 63
3. Maintain
temperature
Long drying time Unstable supply-air volume 2 4 5 40
High LOD Malfunction of timer 2 2 2 8
Low LOD High due-point 3 3 3 27
Non-uniformity of
LOD
Uneven temperature
distribution
3 5 3 45
RPN: Risk Priority Number = S*P*D
Take action when RPN is over 100
Take action when severity is over 5
Remaining critical parameters after taking action; further controls required
Drying Process
Process Potential Cause RPN Recommended Action S P D RPN
1. Set up Disheveled gown of
operator
120 Use long gloves and
goggles
3 2 8 48
Insufficient cleaning of
equipment
112 Change cleaning procedure 7 2 4 56
2. Start
drying
Damage of inlet-air filter 126 Change maintenance
period
7 2 6 84
Damage of thermometer 63 Change calibration period 7 2 3 42
3.Maintain
temperature
Unstable supply-air
volume
40 ― 2 4 5 40
Malfunction of timer 8 ― 2 2 2 8
High dew-point 27 ― 3 3 3 27
Uneven temperature
distribution
45 ― 3 5 3 45
RPN: Risk Priority Number = S*P*D
Should risks
be assessed?
Are there clear rules
for decision making?
e.g. regulations
Yes
“no RM“
Risk assessment not required
(No flexibility)
Follow procedures
(e.g. Standard Operating Procedures)
Document results,
decisions and actions
CONSIDERATIONS
www.drugregulations.org 49
 §211.25 Personnel qualifications. ( a)
◦ Each person engaged in the manufacture, processing, packing, or
holding of a drug product shall have education, training, …………..
◦ Training in cGMP shall be conducted by qualified individuals on a
continuing basis and with sufficient frequency ……………..
 §211.160 General requirements.
◦ Any deviation from the written specifications, standards, sampling
plans, test procedures, or other laboratory control mechanisms
shall be recorded and justified.
9/17/2015. 508/27/2016
 §211.192 Production record review.
◦ Any unexplained discrepancy … shall be thoroughly investigated,
….......
◦ The investigation shall extend to other batches …...........
 §211.46 Ventilation, air filtration, air heating and cooling.
◦ (d) Air-handling systems for the manufacture, processing, and
packing of penicillin shall be completely separate from those for
other drug products for human use.
9/17/2015. 518/27/2016
Should risks
be assessed?
Are there clear rules
for decision making?
e.g. regulations
Yes
“no RM“
Risk assessment not required
(No flexibility)
Follow procedures
(e.g. Standard Operating Procedures)
Document results,
decisions and actions
CONSIDERATIONS
1. What might go wrong?
2. What is the likelihood (probability)
it will go wrong?
3. What are the consequences (severity)?No or
justification needed
Can you answer
the risk assessment
questions?
Yes
“informal RM“
Initiate Risk assessment
(risk identification, analysis & evaluation)
Run risk control
(select appropriate measures)
Agree on a team
(small project)
Select a Risk Management tool
(if appropriate e.g. see ICH Q9 Annex I)
No
“formal RM“
Carry out the
quality risk management process
Document the steps
www.drugregulations.org 52
www.drugregulations.org 53
Presentation prepared by Drug Regulations – a not for profit
organization. Visit www.drugregulations.org for the latest in
Pharmaceuticals.

More Related Content

What's hot

CAPA
CAPA CAPA
Quality risk management : Basic Content
Quality risk management : Basic ContentQuality risk management : Basic Content
Quality risk management : Basic Content
GMP EDUCATION : Not for Profit Organization
 
Risk management using FMEA in pharma
Risk management using FMEA in pharmaRisk management using FMEA in pharma
Risk management using FMEA in pharma
Sandeep Naik
 
Corrective Action & Preventive Action
Corrective Action & Preventive ActionCorrective Action & Preventive Action
Corrective Action & Preventive Action
GMP EDUCATION : Not for Profit Organization
 
Process deviation
Process deviationProcess deviation
Process deviation
GovindarajulaJP
 
Auditing for Sterile Production Area
Auditing for Sterile Production AreaAuditing for Sterile Production Area
Auditing for Sterile Production Area
MANIKANDAN V
 
Hazards and risk management
Hazards and risk managementHazards and risk management
Hazards and risk management
Mukesh Patil
 
Auditing Manufacturing Process and Product and Process Information.pdf
Auditing Manufacturing Process and Product and Process Information.pdfAuditing Manufacturing Process and Product and Process Information.pdf
Auditing Manufacturing Process and Product and Process Information.pdf
Dr. Dinesh Mehta
 
Auditing of vendors and production department
Auditing of vendors and production departmentAuditing of vendors and production department
Auditing of vendors and production department
ArpitSuralkar
 
GMP- APQR Training
GMP- APQR TrainingGMP- APQR Training
GMP- APQR Training
Dr. Amsavel A
 
Deviation QA
Deviation QADeviation QA
Deviation QA
prashik shimpi
 
Hazard and risk management
Hazard and risk managementHazard and risk management
Hazard and risk management
Nikita Amane
 
Quality by design ( QbD)
Quality by design ( QbD)Quality by design ( QbD)
Quality by design ( QbD)
Husain Bin Siddiqui
 
GMP Training: Handling of deviation
GMP Training: Handling of deviationGMP Training: Handling of deviation
GMP Training: Handling of deviation
Dr. Amsavel A
 
Quality Risk Management
Quality Risk ManagementQuality Risk Management
Quality Risk Management
Ruchir Shah
 
Audit Check List
Audit Check ListAudit Check List
Audit Check Listspschandel
 
Audit and regulatory compliance
Audit  and  regulatory complianceAudit  and  regulatory compliance
Audit and regulatory compliance
Archana Chavhan
 
Product quality review
Product quality reviewProduct quality review
Presentation on QRM
Presentation on QRMPresentation on QRM
Presentation on QRM
Neeraj Shrivastava
 

What's hot (20)

CAPA
CAPA CAPA
CAPA
 
Quality risk management : Basic Content
Quality risk management : Basic ContentQuality risk management : Basic Content
Quality risk management : Basic Content
 
Risk management using FMEA in pharma
Risk management using FMEA in pharmaRisk management using FMEA in pharma
Risk management using FMEA in pharma
 
Corrective Action & Preventive Action
Corrective Action & Preventive ActionCorrective Action & Preventive Action
Corrective Action & Preventive Action
 
Process deviation
Process deviationProcess deviation
Process deviation
 
Auditing for Sterile Production Area
Auditing for Sterile Production AreaAuditing for Sterile Production Area
Auditing for Sterile Production Area
 
Hazards and risk management
Hazards and risk managementHazards and risk management
Hazards and risk management
 
Auditing Manufacturing Process and Product and Process Information.pdf
Auditing Manufacturing Process and Product and Process Information.pdfAuditing Manufacturing Process and Product and Process Information.pdf
Auditing Manufacturing Process and Product and Process Information.pdf
 
Auditing of vendors and production department
Auditing of vendors and production departmentAuditing of vendors and production department
Auditing of vendors and production department
 
GMP- APQR Training
GMP- APQR TrainingGMP- APQR Training
GMP- APQR Training
 
Presentation on QRM_NS
Presentation on QRM_NSPresentation on QRM_NS
Presentation on QRM_NS
 
Deviation QA
Deviation QADeviation QA
Deviation QA
 
Hazard and risk management
Hazard and risk managementHazard and risk management
Hazard and risk management
 
Quality by design ( QbD)
Quality by design ( QbD)Quality by design ( QbD)
Quality by design ( QbD)
 
GMP Training: Handling of deviation
GMP Training: Handling of deviationGMP Training: Handling of deviation
GMP Training: Handling of deviation
 
Quality Risk Management
Quality Risk ManagementQuality Risk Management
Quality Risk Management
 
Audit Check List
Audit Check ListAudit Check List
Audit Check List
 
Audit and regulatory compliance
Audit  and  regulatory complianceAudit  and  regulatory compliance
Audit and regulatory compliance
 
Product quality review
Product quality reviewProduct quality review
Product quality review
 
Presentation on QRM
Presentation on QRMPresentation on QRM
Presentation on QRM
 

Similar to Calculation of Risk Priority Numbar

Application of Q R M in Manufacturing Operations
Application of Q R M in Manufacturing Operations Application of Q R M in Manufacturing Operations
Application of Q R M in Manufacturing Operations
GMP EDUCATION : Not for Profit Organization
 
Quality Risk management Application of FMEA
Quality Risk management  Application of FMEAQuality Risk management  Application of FMEA
Quality Risk management Application of FMEA
GMP EDUCATION : Not for Profit Organization
 
Application of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & QualifcationApplication of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & Qualifcation
GMP EDUCATION : Not for Profit Organization
 
ASTM Standard E 2500 for Commissioning and Qualifications
ASTM Standard E 2500 for Commissioning and QualificationsASTM Standard E 2500 for Commissioning and Qualifications
ASTM Standard E 2500 for Commissioning and Qualifications
GMP EDUCATION : Not for Profit Organization
 
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...GMP EDUCATION : Not for Profit Organization
 
Process Validation of Legacy Products
Process Validation of Legacy ProductsProcess Validation of Legacy Products
Process Validation of Legacy Products
GMP EDUCATION : Not for Profit Organization
 
Quality Risk Management 2 brief note
Quality  Risk Management 2 brief noteQuality  Risk Management 2 brief note
Quality Risk Management 2 brief note
RathodBhavansinh
 
Risk analysis
Risk analysis  Risk analysis
Risk analysis
Arvind Kumar
 
Quality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental MonitoringQuality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental Monitoring
GMP EDUCATION : Not for Profit Organization
 
Risk Management in Sterile Environments
Risk Management in Sterile Environments Risk Management in Sterile Environments
Risk Management in Sterile Environments
Tim Sandle, Ph.D.
 
Risk management and environmental monitoring
Risk management and environmental monitoringRisk management and environmental monitoring
Risk management and environmental monitoring
Tim Sandle, Ph.D.
 
US FDA - EU Process Validation : Determination of Number of PPQ Batches
US FDA - EU Process Validation : Determination of Number of PPQ BatchesUS FDA - EU Process Validation : Determination of Number of PPQ Batches
US FDA - EU Process Validation : Determination of Number of PPQ Batches
GMP EDUCATION : Not for Profit Organization
 
Quality risk management
Quality risk managementQuality risk management
Quality risk management
KarunaMane1
 
ICH Q9 QUALITY RISK MANAGEMENT(QRM)
ICH Q9 QUALITY RISK MANAGEMENT(QRM)ICH Q9 QUALITY RISK MANAGEMENT(QRM)
ICH Q9 QUALITY RISK MANAGEMENT(QRM)
saimsoleja
 
Quality Risk Management Dr.A. Amsavel
Quality Risk Management   Dr.A. AmsavelQuality Risk Management   Dr.A. Amsavel
Quality Risk Management Dr.A. Amsavel
Dr. Amsavel A
 
Quality Risk Management - Dr.A. Amsavel
Quality Risk Management  - Dr.A. AmsavelQuality Risk Management  - Dr.A. Amsavel
Quality Risk Management - Dr.A. Amsavel
Dr. Amsavel A
 
FMEA Presentation V1.1
FMEA Presentation V1.1FMEA Presentation V1.1
FMEA Presentation V1.1
Rim View Consulting
 
06 overview of_ra1
06 overview of_ra106 overview of_ra1
06 overview of_ra1
Anil Raina
 
New EMA Guidance on Real Time Release Testing.
New EMA Guidance on Real Time Release Testing.New EMA Guidance on Real Time Release Testing.
New EMA Guidance on Real Time Release Testing.
GMP EDUCATION : Not for Profit Organization
 
11. faliure mode &amp; effect analysis
11. faliure mode &amp; effect analysis11. faliure mode &amp; effect analysis
11. faliure mode &amp; effect analysis
Hakeem-Ur- Rehman
 

Similar to Calculation of Risk Priority Numbar (20)

Application of Q R M in Manufacturing Operations
Application of Q R M in Manufacturing Operations Application of Q R M in Manufacturing Operations
Application of Q R M in Manufacturing Operations
 
Quality Risk management Application of FMEA
Quality Risk management  Application of FMEAQuality Risk management  Application of FMEA
Quality Risk management Application of FMEA
 
Application of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & QualifcationApplication of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & Qualifcation
 
ASTM Standard E 2500 for Commissioning and Qualifications
ASTM Standard E 2500 for Commissioning and QualificationsASTM Standard E 2500 for Commissioning and Qualifications
ASTM Standard E 2500 for Commissioning and Qualifications
 
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
 
Process Validation of Legacy Products
Process Validation of Legacy ProductsProcess Validation of Legacy Products
Process Validation of Legacy Products
 
Quality Risk Management 2 brief note
Quality  Risk Management 2 brief noteQuality  Risk Management 2 brief note
Quality Risk Management 2 brief note
 
Risk analysis
Risk analysis  Risk analysis
Risk analysis
 
Quality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental MonitoringQuality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental Monitoring
 
Risk Management in Sterile Environments
Risk Management in Sterile Environments Risk Management in Sterile Environments
Risk Management in Sterile Environments
 
Risk management and environmental monitoring
Risk management and environmental monitoringRisk management and environmental monitoring
Risk management and environmental monitoring
 
US FDA - EU Process Validation : Determination of Number of PPQ Batches
US FDA - EU Process Validation : Determination of Number of PPQ BatchesUS FDA - EU Process Validation : Determination of Number of PPQ Batches
US FDA - EU Process Validation : Determination of Number of PPQ Batches
 
Quality risk management
Quality risk managementQuality risk management
Quality risk management
 
ICH Q9 QUALITY RISK MANAGEMENT(QRM)
ICH Q9 QUALITY RISK MANAGEMENT(QRM)ICH Q9 QUALITY RISK MANAGEMENT(QRM)
ICH Q9 QUALITY RISK MANAGEMENT(QRM)
 
Quality Risk Management Dr.A. Amsavel
Quality Risk Management   Dr.A. AmsavelQuality Risk Management   Dr.A. Amsavel
Quality Risk Management Dr.A. Amsavel
 
Quality Risk Management - Dr.A. Amsavel
Quality Risk Management  - Dr.A. AmsavelQuality Risk Management  - Dr.A. Amsavel
Quality Risk Management - Dr.A. Amsavel
 
FMEA Presentation V1.1
FMEA Presentation V1.1FMEA Presentation V1.1
FMEA Presentation V1.1
 
06 overview of_ra1
06 overview of_ra106 overview of_ra1
06 overview of_ra1
 
New EMA Guidance on Real Time Release Testing.
New EMA Guidance on Real Time Release Testing.New EMA Guidance on Real Time Release Testing.
New EMA Guidance on Real Time Release Testing.
 
11. faliure mode &amp; effect analysis
11. faliure mode &amp; effect analysis11. faliure mode &amp; effect analysis
11. faliure mode &amp; effect analysis
 

More from GMP EDUCATION : Not for Profit Organization

Risk Assessment for Control of Elemental Impurities.
Risk Assessment for Control of Elemental Impurities.Risk Assessment for Control of Elemental Impurities.
Risk Assessment for Control of Elemental Impurities.
GMP EDUCATION : Not for Profit Organization
 
Pharmaceutical Quality System
Pharmaceutical Quality System Pharmaceutical Quality System
Pharmaceutical Quality System
GMP EDUCATION : Not for Profit Organization
 
New WHO Guidance on Analytical Method Validation
New WHO Guidance on Analytical Method ValidationNew WHO Guidance on Analytical Method Validation
New WHO Guidance on Analytical Method Validation
GMP EDUCATION : Not for Profit Organization
 
Blend and Content Uniformity : Industry Recommendations for Way Forward
Blend and Content Uniformity : Industry Recommendations for Way ForwardBlend and Content Uniformity : Industry Recommendations for Way Forward
Blend and Content Uniformity : Industry Recommendations for Way Forward
GMP EDUCATION : Not for Profit Organization
 
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
GMP EDUCATION : Not for Profit Organization
 
WHO Guidance on Preparation of Laboratory Information File
WHO  Guidance on Preparation of Laboratory Information FileWHO  Guidance on Preparation of Laboratory Information File
WHO Guidance on Preparation of Laboratory Information File
GMP EDUCATION : Not for Profit Organization
 
US FDA Quality Metrics Technical Conformance Guide
US FDA  Quality Metrics Technical  Conformance GuideUS FDA  Quality Metrics Technical  Conformance Guide
US FDA Quality Metrics Technical Conformance Guide
GMP EDUCATION : Not for Profit Organization
 
New PICS Guidance on Data Integrity and Management.
New PICS Guidance on Data Integrity and Management.New PICS Guidance on Data Integrity and Management.
New PICS Guidance on Data Integrity and Management.
GMP EDUCATION : Not for Profit Organization
 
New WHO Guidance on CS Validation
New WHO Guidance on CS ValidationNew WHO Guidance on CS Validation
New WHO Guidance on CS Validation
GMP EDUCATION : Not for Profit Organization
 
New WHO Guidance on Process Validation
New WHO Guidance on Process ValidationNew WHO Guidance on Process Validation
New WHO Guidance on Process Validation
GMP EDUCATION : Not for Profit Organization
 
Presentation on US FDA Data Integrity Guidance.
Presentation on US FDA  Data Integrity Guidance.Presentation on US FDA  Data Integrity Guidance.
Presentation on US FDA Data Integrity Guidance.
GMP EDUCATION : Not for Profit Organization
 
Understanding and Preventing Clean Room Contamination
Understanding and Preventing Clean Room ContaminationUnderstanding and Preventing Clean Room Contamination
Understanding and Preventing Clean Room Contamination
GMP EDUCATION : Not for Profit Organization
 
WHO Guidance on Technology Transfers
WHO Guidance on Technology TransfersWHO Guidance on Technology Transfers
WHO Guidance on Technology Transfers
GMP EDUCATION : Not for Profit Organization
 
Who Guidelines for Preparing SMF
Who Guidelines for Preparing  SMFWho Guidelines for Preparing  SMF
Who Guidelines for Preparing SMF
GMP EDUCATION : Not for Profit Organization
 
Validation of Microbiological Methods
Validation of Microbiological MethodsValidation of Microbiological Methods
Validation of Microbiological Methods
GMP EDUCATION : Not for Profit Organization
 
Presentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QPPresentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QP
GMP EDUCATION : Not for Profit Organization
 
WHO Good Practices for Microbiology Labs.
WHO Good Practices for Microbiology Labs.WHO Good Practices for Microbiology Labs.
WHO Good Practices for Microbiology Labs.
GMP EDUCATION : Not for Profit Organization
 
Who Guidance on Quality Risk Management
Who Guidance on Quality Risk ManagementWho Guidance on Quality Risk Management
Who Guidance on Quality Risk Management
GMP EDUCATION : Not for Profit Organization
 
Water for Pharmaceutical Purposes - New USP Requriements
Water for Pharmaceutical Purposes - New USP  RequriementsWater for Pharmaceutical Purposes - New USP  Requriements
Water for Pharmaceutical Purposes - New USP Requriements
GMP EDUCATION : Not for Profit Organization
 
Who Guidance on Process Validation for Non Serile Pharmaceuticals
Who Guidance on Process Validation for Non Serile PharmaceuticalsWho Guidance on Process Validation for Non Serile Pharmaceuticals
Who Guidance on Process Validation for Non Serile Pharmaceuticals
GMP EDUCATION : Not for Profit Organization
 

More from GMP EDUCATION : Not for Profit Organization (20)

Risk Assessment for Control of Elemental Impurities.
Risk Assessment for Control of Elemental Impurities.Risk Assessment for Control of Elemental Impurities.
Risk Assessment for Control of Elemental Impurities.
 
Pharmaceutical Quality System
Pharmaceutical Quality System Pharmaceutical Quality System
Pharmaceutical Quality System
 
New WHO Guidance on Analytical Method Validation
New WHO Guidance on Analytical Method ValidationNew WHO Guidance on Analytical Method Validation
New WHO Guidance on Analytical Method Validation
 
Blend and Content Uniformity : Industry Recommendations for Way Forward
Blend and Content Uniformity : Industry Recommendations for Way ForwardBlend and Content Uniformity : Industry Recommendations for Way Forward
Blend and Content Uniformity : Industry Recommendations for Way Forward
 
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
 
WHO Guidance on Preparation of Laboratory Information File
WHO  Guidance on Preparation of Laboratory Information FileWHO  Guidance on Preparation of Laboratory Information File
WHO Guidance on Preparation of Laboratory Information File
 
US FDA Quality Metrics Technical Conformance Guide
US FDA  Quality Metrics Technical  Conformance GuideUS FDA  Quality Metrics Technical  Conformance Guide
US FDA Quality Metrics Technical Conformance Guide
 
New PICS Guidance on Data Integrity and Management.
New PICS Guidance on Data Integrity and Management.New PICS Guidance on Data Integrity and Management.
New PICS Guidance on Data Integrity and Management.
 
New WHO Guidance on CS Validation
New WHO Guidance on CS ValidationNew WHO Guidance on CS Validation
New WHO Guidance on CS Validation
 
New WHO Guidance on Process Validation
New WHO Guidance on Process ValidationNew WHO Guidance on Process Validation
New WHO Guidance on Process Validation
 
Presentation on US FDA Data Integrity Guidance.
Presentation on US FDA  Data Integrity Guidance.Presentation on US FDA  Data Integrity Guidance.
Presentation on US FDA Data Integrity Guidance.
 
Understanding and Preventing Clean Room Contamination
Understanding and Preventing Clean Room ContaminationUnderstanding and Preventing Clean Room Contamination
Understanding and Preventing Clean Room Contamination
 
WHO Guidance on Technology Transfers
WHO Guidance on Technology TransfersWHO Guidance on Technology Transfers
WHO Guidance on Technology Transfers
 
Who Guidelines for Preparing SMF
Who Guidelines for Preparing  SMFWho Guidelines for Preparing  SMF
Who Guidelines for Preparing SMF
 
Validation of Microbiological Methods
Validation of Microbiological MethodsValidation of Microbiological Methods
Validation of Microbiological Methods
 
Presentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QPPresentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QP
 
WHO Good Practices for Microbiology Labs.
WHO Good Practices for Microbiology Labs.WHO Good Practices for Microbiology Labs.
WHO Good Practices for Microbiology Labs.
 
Who Guidance on Quality Risk Management
Who Guidance on Quality Risk ManagementWho Guidance on Quality Risk Management
Who Guidance on Quality Risk Management
 
Water for Pharmaceutical Purposes - New USP Requriements
Water for Pharmaceutical Purposes - New USP  RequriementsWater for Pharmaceutical Purposes - New USP  Requriements
Water for Pharmaceutical Purposes - New USP Requriements
 
Who Guidance on Process Validation for Non Serile Pharmaceuticals
Who Guidance on Process Validation for Non Serile PharmaceuticalsWho Guidance on Process Validation for Non Serile Pharmaceuticals
Who Guidance on Process Validation for Non Serile Pharmaceuticals
 

Recently uploaded

Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 

Recently uploaded (20)

Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 

Calculation of Risk Priority Numbar

  • 1. www.drugregulations.org 1 Presentation prepared by Drug Regulations – a not for profit organization. Visit www.drugregulations.org for the latest in Pharmaceuticals.
  • 2.  This presentation will cover 1. Overview of Quality Risk Management Process & Tools 2. FMEA Overview 3. Calculation of RPN 4. Case Stud ◦ Drying Process www.drugregulations.org 2
  • 3.  Risk ◦ Combination of ◦ Probability of occurrence of harm and ◦ Severity of that harm.
  • 4.  Any circumstances which can cause an adverse health effect. ◦ Research , Pre-clinical , Clinical ◦ Production ◦ Control ◦ Distribution
  • 5.  Which consequence is more severe? ◦ 300 lives lost in single, fiery plane crash. ◦ 300 lives lost on roads over a weekend. ◦ 300 lives potentially lost from cancer within the next 20 years  Which probability is probable? What does a “30% chance of rain tomorrow” mean? ◦ 30% of the days like tomorrow will have at least a trace of rain. ◦ 30% of the area will have rain tomorrow. ◦ 30% of the time tomorrow, it will rain.
  • 6. Hazard may cause harm Hazard may not cause harm uncertainty Hazard is less likely to cause harm Manage risks in relation to probability Lack of, or inadequate knowledge
  • 7. Time  ProcessParameter Lower Specification Limit (LSL) Upper Specification Limit (USL) today Uncertainty RISK: For a given severity of risk event, what are the chances (probability) of exceeding the USL in the next period of time? Tomorrow ?
  • 8. Time  ProcessParameter Lower Specification Limit (LSL) Upper Specification Limit (USL) today Uncertainty RISK: Control options are scenarios for risk management. Note that this scenario shows the best estimate is below the USL. Tomorrow ?
  • 9. Time  ProcessParameter Lower Specification Limit (LSL) Upper Specification Limit (USL) today Uncertainty Take a cut at a moment in time: Risk has a distribution. Tomorrow ?
  • 10.  Risk Identification What might go wrong?  Risk Analysis What is the likelihood (probability) it will go wrong  What are the consequences (severity)?  Risk Evaluation What is the level of risk? Any mitigating factors? Risk Assessment www.drugregulations.org 10 Risk Review RiskCommunication Risk Assessment Risk Evaluation unacceptable Risk Control Risk Analysis Risk Reduction Risk Identification Review Events Risk Acceptance Initiate Quality Risk Management Process Output / Result of the Quality Risk Management Process RiskManagementtools  Risk Reduction Mitigation or avoidance of quality risk Elimination of risks, where appropriate Risk Control  Risk Acceptance Acceptance of Residual Risk
  • 11.  System Risk (facility & people) ◦ e.g. interfaces, operators risk, environment, components such as equipment, IT, design elements  System Risk (organisation) ◦ e.g. Quality systems, controls, measurements, documentation, regulatory compliance  Process Risk ◦ e.g. process operations and quality parameters  Product Risk (safety & efficacy) ◦ e.g. quality attributes: measured data according to specifications
  • 12. The evaluation of the risk to quality should be based on scientific knowledge and ultimately link to the protection of the patient The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk ICH Q9
  • 13.
  • 14.  Supporting statistical tools ◦ Acceptance Control Charts (see ISO 7966) ◦ Control Charts (for example)  Control Charts with Arithmetic Average and Warning Limits (see ISO 7873)  Cumulative Sum Charts; “CuSum” (see ISO 7871)  Shewhart Control Charts (see ISO 8258)  Weighted Moving Average ◦ Pareto Charts ◦ Process Capability Analysis ◦ Histograms ◦ Design of Experiments (DOE) ◦ Use others that you are familiar with…. www.drugregulations.org 14
  • 15. 158/27/2016 Drug Regulations : Online Resource for Latest Information
  • 16.  Systematic Method for Identification and Prevention of  Product & Process Problems before they occur  Focused on Preventing Defects  Ideally conducted in Product & Process Design Stage  Conducting on existing products & processes yields substantial results. 168/27/2016 Drug Regulations : Online Resource for Latest Information
  • 17.  First formal FEMA was conducted in Aerospace Industry in 1960’s  Became key tool for improving safety of chemical processes  Safety FMEA today is a key tool to prevent safety accidents & incidents  Engineers have always used FMEA to identify potential failures of product & processes  Automotive Industry used FMEA for Quality Improvement 178/27/2016 Drug Regulations : Online Resource for Latest Information
  • 18.  Essential to have documented Data and Information about Product & Process  Otherwise it becomes a guessing game based on opinions.  FMEA will then focus on wrong failure modes  FMEA should be based on facts : on DATA 188/27/2016 Drug Regulations : Online Resource for Latest Information
  • 19.  To look for all different ways in which a product or process can fail  Failures are not limited to products  Failures can occur when the user makes a mistake  These failures should also be included in FMEA 198/27/2016 Drug Regulations : Online Resource for Latest Information
  • 20.  Ways in which a product or process can fail are called FAILURE MODES  Each FAILURE MODE has a potential effect  Some effects are more likely to occur than others – each failure mode has a probability  Each FAILURE MODE has relative RISK associated with it. 208/27/2016 Drug Regulations : Online Resource for Latest Information
  • 21.  FMEA process is way to identify the failures, effects, and risks within a process or product and then eliminate or reduce them. 218/27/2016 Drug Regulations : Online Resource for Latest Information
  • 22.  Process Step : Pre-mixing  Failure Mode : Mixing time  Effect : Not meet specifications of content uniformity  Risk Reduction: IPC measure of content uniformity  Comments: Effect on efficacy 228/27/2016 Drug Regulations : Online Resource for Latest Information
  • 23.  Process Step : Pre-mixing granulation  Failure Mode : speed of adding water  Effect : Not meet specifications of dissolution and degradation  Risk Reduction: Use of dosing pump  Comments: Appropriate granulation 238/27/2016 Drug Regulations : Online Resource for Latest Information
  • 24.  Process Step : Pre-mixing granulation  Failure Mode : Manner of adding water  Effect : Not meet specifications of dissolution and degradation  Risk Reduction: Install a spray nozzle  Comments: Appropriate granulation 248/27/2016 Drug Regulations : Online Resource for Latest Information
  • 25.  Process Step : Granulation  Failure Mode : Kneading Time  Effect : Not meet dissolution specification  Risk Reduction: Reduce Personal fluctuations  Comments: Operator knowledge , power consumption, difficult to automate 258/27/2016 Drug Regulations : Online Resource for Latest Information
  • 26.  Process Step : Granulation  Failure Mode : Power consumption  Effect : Not meet dissolution specification  Risk Reduction: Try to get optimum kneading time  Comments: Depends on material properties 268/27/2016 Drug Regulations : Online Resource for Latest Information
  • 27.  Process Step : Granulation  Failure Mode : Quality of excipients  Effect : All parameters may need re-evaluation  Risk Reduction: Internal specifications for physical parameters  Comments: Supplier qualification 278/27/2016 Drug Regulations : Online Resource for Latest Information
  • 28.  Process Step : Granulation drying  Failure Mode : Water Content  Effect : Not meet degradation specification  Risk Reduction: On line NIR , IPC measurements,  Comments: Indirect , Time consuming 288/27/2016 Drug Regulations : Online Resource for Latest Information
  • 29.  The relative risk of a failure and its effects is determined by three factors  Severity: The consequences of the failure should it occur  Occurrence: The probability or the frequency of the failure occurring  Detection : The probability of the failure being detected before the impact of the effect is realized. 298/27/2016 Drug Regulations : Online Resource for Latest Information
  • 30.  Each Potential Failure Mode is rated in each of the three factors on a scale ranging from 1 to 10 , low to high.  Risk Priority Number( RPN) is determined by multiplying the ranking of the three factors ( severity X occurrence X detection )  The RPN is determined for each potential failure and each effect. 308/27/2016 Drug Regulations : Online Resource for Latest Information
  • 31.  The RPN is used to rank the need for corrective action to eliminate or reduce the potential failure modes.  Failure modes with highest RPN should be attended first  Special attention should be given when the severity ranking is high : 9 or 10  RPN will range from 1 to 1000 for each failure mode. 318/27/2016 Drug Regulations : Online Resource for Latest Information
  • 32.  Once corrective action is taken , a new RPN is determined by re-evaluating the severity , occurrence and detection.  The new RPN is called “ Resulting RPN”  Improvements and corrective actions must continue until the “ Resulting RPN is at an acceptable level for all potential failure modes. 328/27/2016 Drug Regulations : Online Resource for Latest Information
  • 34. Potential Areas of Use(s)  Prioritize risks  Monitor the effectiveness of risk control activities  Equipment and facilities  Analyse a manufacturing process to identify high-risk steps or critical parameters RNP: Risk Priority Number 348/27/2016 Drug Regulations : Online Resource for Latest Information
  • 35. 1. Review the Process or Product 2. Brainstorm potential failure modes 3. List Potential effects of each failure mode 4. Assign a Severity Ranking for each failure mode 5. Assign Occurrence Ranking for each failure mode 6. Assign detection ranking for each failure mode or effect 7. Calculate the RPN for each effect 8. Prioritize the Failure Modes for Action 9. Take action to eliminate or reduce high risk failure modes 10. Calculate the RPN again as the failure modes are reduced or eliminated. 358/27/2016 Drug Regulations : Online Resource for Latest Information
  • 37. 10 Dangerously High Failure could lead to death or permanent injury to the customer. Financial: >$1,000,000 9 Extremely high Failure could lead to injury to the customer. Failure would create non- compliance with registered specifications. Failure likely to lead to recall. Financial: $1,000,000 8 Very High Failure could lead to adverse reaction for customer. Failure would create noncompliance with GMP regulations or product registrations. Failure possible to lead to recall. Financial: $500,000 7 High Failure leads to customer percept ion of safety issue. Failure renders individual unit(s) unusable. Failure causes a high degree of customer dissatisfaction. Recall for business reasons possible but Authority required recall unlikely. Financial: $100,000 6 Moderate Failure causes a high degree of customer dissatisfaction and numerous complaints. Failure unlikely to lead to recall. Financial: $50,000 5 Low Failure likely to cause isolated customer complaints. Financial: $10,000 4 Very Low Failure relates to non-dosage form issues (like minor packaging problems) and can be easily overcome by the customer. Financial: $5,000 3 Minor Failure could be noticed by the customer but is unlikely to be perceived as significant enough to warrant a complaint. 2 Very Minor Failure not readily apparent to the customer. Financial: <$1,000 1 None Failure would not be noticeable to the customer. Financial: none
  • 38. 10 Very High: Failure is almost inevitable More than one occurrence per day or a probability of more than three occurrences in 10 units (Cpk < 0.33 or <1σ). 9 One occurrence every three to four days or a probability of three occurrences in 10 units (Cpk ~ 0.33 or ~1 σ). 8 High: Repeated failures One occurrence per week or a probability of 5 occurrences in 100 units (Cpk ~ 0.67 or ~2 σ). 7 One occurrence every month or one occurrence in 100 units (Cpk ~ 0.83 ~2.5 σ). 6 Moderate: Occasional Failures One occurrence every three months or three occurrences in 1,000 units (Cpk ~ 1.00 or ~ 3 σ). 5 One occurrence every six months to one year or one occurrence in 10,000 units (Cpk ~ 1.17 or ~ 3.5 σ). 4 One occurrence per year or six occurrences in 100,000 units (Cpk ~ 1.33 or ~ 4 σ). 3 Low: Relatively few Failures One occurrence every one to three years or six occurrences in 10,000,000 units (Cpk ~ 1.67 or ~5 σ). 2 One occurrence every three to five years or 2 occurrences in 1,000,000,000 units (Cpk ~ 2.00 OR ~6 σ). 1 Remote: Failure is unlikely One occurrence in greater than five years or less than two occurrences in 1,000,000,000 units (Cpk > 2.00 OR >6 σ). For batch failures use the time scale for unit failures use the unit scale.
  • 39. 10 Absolute Uncertainty The product is not inspected or the defect caused by the failure is not detectable. 9 Very Remote Product is sampled, inspected, and released based on Acceptable Quality Level (AQL) sampling plans. 8 Remote Product is accepted based on no defects in a sample. 7 Very Low Product is 100% manually inspected in the process. 6 Low Product is 100% manually inspected using go/no-go or other mistake-proofing gauges. 5 Moderate Some Statistical Process Control (SPC) is used in the process and product is final inspected off-line. 4 Moderately High SPC is used and there is immediate reaction to out-of-control conditions. 3 High An effective SPC program is in place with process capabilities (Cpk) greater than 1.33. 2 Very High All product is 100% automatically inspected. 1 Almost Certain The defect is obvious and there is 100% automatic inspection with regular calibration and preventive maintenance of the inspection equipment.
  • 40. • 10 Extreme • Predicted to cause severe impact to quality (Product out of specifications, no Expert Statement possible) • 7 High • Predicted to cause significant impact on quality (Failure to meet specifications, no Stability data, Expert Statement possible) • 3 Moderate • Predicted to cause minor impact on quality (Failure to meet specifications, Stability data available) • 1 Low • Predicted to have no/minor impact on quality of the product (Quality within specifications) 9/17/2015. 408/27/2016
  • 41. • 8 Regular failures • Expected to happen regularly • 4 Repeated failures • Expected to happen in a low frequency • 2 Occasional failures • Expected to happen infrequently • 1 Unlikely failures • Unlikely to happen 9/17/2015. 418/27/2016
  • 42. • 4 Normally not detected • Failure very likely to be overlooked, hence not detected (no technical solution, no manual control) • 3 Likely not detected • Failure may be overseen (manual control, spot checks) • 2 Regularly detected • Failure will normally be detected (manual control, routine work with statistical control) • 1 Always detected • Failure can and will be detected in all cases (monitoring, technical solution available) 428/27/2016
  • 44.  Severity (S) ◦ Link to end product functional failure ◦ Medical Department involvement  Probability (P) ◦ Use historical data ◦ Similar processes products  Detection ◦ Validation studies ◦ Historical data Drying Process 448/27/2016
  • 45. Rankin g Severity (S) Probability (P) Detection (D) 10 Death More than once a day Impossible to detect 9 ↓ 3 – 4 times a day Remote 8 Permanent injury Once a week Very slight 7 ↓ Once a month Slight 6 Temporary injury Once in three month Low 5 ↓ Once in half – one year Medium 4 Reported/ dissatisfied Once a year Moderately high 3 ↓ Once in 1 – 3 years High 2 Notice/ no report Once in 3 – 5 years Very High 1 ↓ Less than once in 5 years Virtually certain Drying Process 9/17/2015. 45
  • 46. Process Potential Failure Mode Potential Cause S P D RPN 1. Set up Contamination Disheveled gown of operator Insufficient cleaning of equipment 2. Start drying Contamination Damage of inlet-air filter Degradation of product Damage of thermometer 3. Maintain temperature Long drying time Unstable supply-air volume High Loss On Drying (LOD) Damage of timer Low LOD High dew-point Non-uniformity of LOD Uneven temperature distribution Drying Process RPN: Risk Priority Number = S*P*D
  • 47. Existing controls: IPC of LOD and degradation product after drying process Drying Process Process Potential Failure Mode Potential Cause S P D RPN 1. Set up Contamination Disheveled gown of operator 3 5 8 120 Insufficient cleaning of equipment 7 2 8 112 2. Start drying Contamination Damage of inlet-air filter 7 3 6 126 Degradation of product Damage of thermometer 7 3 3 63 3. Maintain temperature Long drying time Unstable supply-air volume 2 4 5 40 High LOD Malfunction of timer 2 2 2 8 Low LOD High due-point 3 3 3 27 Non-uniformity of LOD Uneven temperature distribution 3 5 3 45 RPN: Risk Priority Number = S*P*D
  • 48. Take action when RPN is over 100 Take action when severity is over 5 Remaining critical parameters after taking action; further controls required Drying Process Process Potential Cause RPN Recommended Action S P D RPN 1. Set up Disheveled gown of operator 120 Use long gloves and goggles 3 2 8 48 Insufficient cleaning of equipment 112 Change cleaning procedure 7 2 4 56 2. Start drying Damage of inlet-air filter 126 Change maintenance period 7 2 6 84 Damage of thermometer 63 Change calibration period 7 2 3 42 3.Maintain temperature Unstable supply-air volume 40 ― 2 4 5 40 Malfunction of timer 8 ― 2 2 2 8 High dew-point 27 ― 3 3 3 27 Uneven temperature distribution 45 ― 3 5 3 45 RPN: Risk Priority Number = S*P*D
  • 49. Should risks be assessed? Are there clear rules for decision making? e.g. regulations Yes “no RM“ Risk assessment not required (No flexibility) Follow procedures (e.g. Standard Operating Procedures) Document results, decisions and actions CONSIDERATIONS www.drugregulations.org 49
  • 50.  §211.25 Personnel qualifications. ( a) ◦ Each person engaged in the manufacture, processing, packing, or holding of a drug product shall have education, training, ………….. ◦ Training in cGMP shall be conducted by qualified individuals on a continuing basis and with sufficient frequency ……………..  §211.160 General requirements. ◦ Any deviation from the written specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms shall be recorded and justified. 9/17/2015. 508/27/2016
  • 51.  §211.192 Production record review. ◦ Any unexplained discrepancy … shall be thoroughly investigated, …....... ◦ The investigation shall extend to other batches …...........  §211.46 Ventilation, air filtration, air heating and cooling. ◦ (d) Air-handling systems for the manufacture, processing, and packing of penicillin shall be completely separate from those for other drug products for human use. 9/17/2015. 518/27/2016
  • 52. Should risks be assessed? Are there clear rules for decision making? e.g. regulations Yes “no RM“ Risk assessment not required (No flexibility) Follow procedures (e.g. Standard Operating Procedures) Document results, decisions and actions CONSIDERATIONS 1. What might go wrong? 2. What is the likelihood (probability) it will go wrong? 3. What are the consequences (severity)?No or justification needed Can you answer the risk assessment questions? Yes “informal RM“ Initiate Risk assessment (risk identification, analysis & evaluation) Run risk control (select appropriate measures) Agree on a team (small project) Select a Risk Management tool (if appropriate e.g. see ICH Q9 Annex I) No “formal RM“ Carry out the quality risk management process Document the steps www.drugregulations.org 52
  • 53. www.drugregulations.org 53 Presentation prepared by Drug Regulations – a not for profit organization. Visit www.drugregulations.org for the latest in Pharmaceuticals.